MBC 101: Tumor Microenvironment with Dr. Amy Beumer
Have you ever wondered how our cancer metastasizes? Why is it that some treatments just don’t work? Can we as patients living with MBC alter cellular level activity? In this episode, you will hear the answers to these questions and more. Join us as we take a step back to the basics of tumor microenvironment with our guest, Dr. Amy Beumer, who will break down the science into smaller, digestible bites. In this lively discussion, Dr. Amy explains the how and the why of this tough topic. You will hear her say “This is fun” and use engaging, relatable metaphors like “Picture your neighborhood and that one neighbor…..” By the end, I assure you that you’ll walk away with a deeper understanding of tumor microenvironment than when you started.
Pull up a chair, listen in your car, or on your daily walk, we are with you wherever you listen to your podcasts. Terms and other resources are provided in the episode notes.
Tumor-Agnostic Therapies: Is The TAPUR Study Right For You?
For our Season 9 opening episode, we're learning about agnostic treatments in cancer with Dr. Richard Schilsky of ASCO, who discusses the TAPUR Study. You may wonder, what is TAPUR and how does it relate to agnostic treatments? The pioneer behind the study, Dr. Schilsky, explains clinical trials for agnostic therapeutics, how you can join a TAPUR trial, and what to expect.
Tumor-Agnostic Therapies: Is This a Paradigm Shift in Cancer Care?
Do tumor-agnostic therapies represent a radical shift in oncology? Join us on this 1st part of a 2-part series as Dr. Joshua Drago of MSKCC answers this question and points out the advantages as well as the treatment limitations of agnostic therapeutics.
Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
We are thrilled to present an audio version of SHARE Cancer Support’s webinar “Report Back from ASCO 2024: Latest Updates on HR+ Metastatic Breast Cancer (MBC)”.
This episode is an in-depth report from the ASCO 2024 Annual Meeting, featuring the latest advancements and research in HR+ MBC. Hear from Dr. Kevin Kalinsky as we dive into the findings from the DESTINY-Breast06 and postMONARCH trials, exploring their implications and potential impact on treatment strategies.
Tissue Donation - You can help advance MBC research
Today we talk with breast cancer researcher Dr. Steffi Oesterreich, clinical coordinator Lori Miller, and MBC advocates Stephanie Walker and Christine Hodgdon to learn more about tissue donation programs and how they can help accelerate scientific research. Tissue donation programs ask patients to consider donating their tissues, including organs, soon after we die to help researchers better understand how breast cancer continues to spread and how to slow it down or stop it altogether. Donating our tissue is one way we can help thousands of other women and men with MBC to live longer with higher quality of life.
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.
Twisted Pink and a Dash of Joy
We are ending season 2 on a positive note with a dash of joy from Dar Finkelstein and a conversation with our Trailblazer of the Month Caroline Johnson, founder of Kentucky-based non-profit organization Twisted Pink whose sole mission is to raise funds for MBC. Even though there is still no cure, our odds of getting to a cure through better funded research and science are improving because of the contributions of allies like Caroline Johnson.